Shanghai Vitalgen BioPharma Co., Ltd.
Quick facts
Phase 3 pipeline
- VGR-R01 · Cardiovascular
VGR-R01 is a small molecule drug that targets the renin-angiotensin system.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Shanghai Vitalgen BioPharma Co., Ltd. portfolio CI brief
- Shanghai Vitalgen BioPharma Co., Ltd. pipeline updates RSS
Frequently asked questions about Shanghai Vitalgen BioPharma Co., Ltd.
What is Shanghai Vitalgen BioPharma Co., Ltd.'s pipeline?
Shanghai Vitalgen BioPharma Co., Ltd. has 1 drugs in Phase 3, 0 in Phase 2, 5 in Phase 1. Late-stage candidates include VGR-R01.
Related
- Sector hub: All tracked pharma companies